Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 37 to 46 of 46 entries
Sorted by: Best Match Show Resources per page
In the news: Treatment guidelines and positive trials at ECTRIMS.

Nature reviews. Neurology

Fyfe I.
PMID: 27713489
Nat Rev Neurol. 2016 Nov;12(11):614. doi: 10.1038/nrneurol.2016.154. Epub 2016 Oct 07.

No abstract available.

Cite
Fyfe I. In the news: Treatment guidelines and positive trials at ECTRIMS. Nat Rev Neurol. 2016;12(11):614doi: 10.1038/nrneurol.2016.154.
Fyfe, I. (2016). In the news: Treatment guidelines and positive trials at ECTRIMS. Nature reviews. Neurology, 12(11), 614. https://doi.org/10.1038/nrneurol.2016.154
Fyfe, Ian. "In the news: Treatment guidelines and positive trials at ECTRIMS." Nature reviews. Neurology vol. 12,11 (2016): 614. doi: https://doi.org/10.1038/nrneurol.2016.154
Fyfe I. In the news: Treatment guidelines and positive trials at ECTRIMS. Nat Rev Neurol. 2016 Nov;12(11):614. doi: 10.1038/nrneurol.2016.154. Epub 2016 Oct 07. PMID: 27713489.
Copy Download .nbib Format: NLM
The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study.

Journal of medical Internet research

Simacek KF, Ko JJ, Moreton D, Varga S, Johnson K, Katic BJ.
PMID: 30377144
J Med Internet Res. 2018 Oct 30;20(10):e11168. doi: 10.2196/11168.

BACKGROUND: In the United States, people with relapsing-remitting multiple sclerosis (RRMS) can face difficulty accessing disease-modifying therapies (DMTs) because of insurance, pharmacy, or provider policies. These barriers have been associated with poor adherence and negative health outcomes.OBJECTIVE: The goals...

Cite
Simacek KF, Ko JJ, Moreton D, et al. The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study. J Med Internet Res. 2018;20(10):e11168doi: 10.2196/11168.
Simacek, K. F., Ko, J. J., Moreton, D., Varga, S., Johnson, K., & Katic, B. J. (2018). The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study. Journal of medical Internet research, 20(10), e11168. https://doi.org/10.2196/11168
Simacek, Kristina F, et al. "The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study." Journal of medical Internet research vol. 20,10 (2018): e11168. doi: https://doi.org/10.2196/11168
Simacek KF, Ko JJ, Moreton D, Varga S, Johnson K, Katic BJ. The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study. J Med Internet Res. 2018 Oct 30;20(10):e11168. doi: 10.2196/11168. PMID: 30377144; PMCID: PMC6234348.
Copy Download .nbib Format: NLM
Facing the urgency of therapies for progressive MS - a Progressive MS Alliance proposal.

Nature reviews. Neurology

Dangond F, Donnelly A, Hohlfeld R, Lubetzki C, Kohlhaas S, Leocani L, Ciccarelli O, Stankoff B, Sormani MP, Chataway J, Bozzoli F, Cucca F, Melton L, Coetzee T, Salvetti M.
PMID: 33483719
Nat Rev Neurol. 2021 Mar;17(3):185-192. doi: 10.1038/s41582-020-00446-9. Epub 2021 Jan 22.

Therapies for infiltrative inflammation in multiple sclerosis (MS) have advanced greatly, but neurodegeneration and compartmentalized inflammation remain virtually untargeted as in other diseases of the nervous system. Consequently, many therapies are available for the relapsing-remitting form of MS, but...

Cite
Dangond F, Donnelly A, Hohlfeld R, et al. Facing the urgency of therapies for progressive MS - a Progressive MS Alliance proposal. Nat Rev Neurol. 2021;17(3):185-192doi: 10.1038/s41582-020-00446-9.
Dangond, F., Donnelly, A., Hohlfeld, R., Lubetzki, C., Kohlhaas, S., Leocani, L., Ciccarelli, O., Stankoff, B., Sormani, M. P., Chataway, J., Bozzoli, F., Cucca, F., Melton, L., Coetzee, T., & Salvetti, M. (2021). Facing the urgency of therapies for progressive MS - a Progressive MS Alliance proposal. Nature reviews. Neurology, 17(3), 185-192. https://doi.org/10.1038/s41582-020-00446-9
Dangond, Fernando, et al. "Facing the urgency of therapies for progressive MS - a Progressive MS Alliance proposal." Nature reviews. Neurology vol. 17,3 (2021): 185-192. doi: https://doi.org/10.1038/s41582-020-00446-9
Dangond F, Donnelly A, Hohlfeld R, Lubetzki C, Kohlhaas S, Leocani L, Ciccarelli O, Stankoff B, Sormani MP, Chataway J, Bozzoli F, Cucca F, Melton L, Coetzee T, Salvetti M. Facing the urgency of therapies for progressive MS - a Progressive MS Alliance proposal. Nat Rev Neurol. 2021 Mar;17(3):185-192. doi: 10.1038/s41582-020-00446-9. Epub 2021 Jan 22. PMID: 33483719.
Copy Download .nbib Format: NLM
Real-life clinical practice studies in multiple sclerosis.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

Costa-Frossard L.
PMID: 33709885
Farm Hosp. 2021 Mar 08;45(2):51-52. doi: 10.7399/fh.11663.

No abstract available.

Cite
Costa-Frossard L. Estudios de práctica clínica real en esclerosis múltiple. Real-life clinical practice studies in multiple sclerosis. Farm Hosp. 2021;45(2):51-52doi: 10.7399/fh.11663.
Costa-Frossard, L. (2021). Estudios de práctica clínica real en esclerosis múltiple. Real-life clinical practice studies in multiple sclerosis. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 45(2), 51-52. https://doi.org/10.7399/fh.11663
Costa-Frossard, Lucienne. "Estudios de práctica clínica real en esclerosis múltiple." Real-life clinical practice studies in multiple sclerosis. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria vol. 45,2 (2021): 51-52. doi: https://doi.org/10.7399/fh.11663
Costa-Frossard L. Estudios de práctica clínica real en esclerosis múltiple. Real-life clinical practice studies in multiple sclerosis. Farm Hosp. 2021 Mar 08;45(2):51-52. doi: 10.7399/fh.11663. PMID: 33709885.
Copy Download .nbib Format: NLM
Sequencing of and escalation paradigms for MS therapies: time for a rethink?.

Journal of neurology, neurosurgery, and psychiatry

Taylor BV.
PMID: 34103341
J Neurol Neurosurg Psychiatry. 2021 Sep;92(9):913. doi: 10.1136/jnnp-2020-325811. Epub 2021 Jun 08.

No abstract available.

Cite
Taylor BV. Sequencing of and escalation paradigms for MS therapies: time for a rethink?. J Neurol Neurosurg Psychiatry. 2021;92(9):913doi: 10.1136/jnnp-2020-325811.
Taylor, B. V. (2021). Sequencing of and escalation paradigms for MS therapies: time for a rethink?. Journal of neurology, neurosurgery, and psychiatry, 92(9), 913. https://doi.org/10.1136/jnnp-2020-325811
Taylor, Bruce V. "Sequencing of and escalation paradigms for MS therapies: time for a rethink?." Journal of neurology, neurosurgery, and psychiatry vol. 92,9 (2021): 913. doi: https://doi.org/10.1136/jnnp-2020-325811
Taylor BV. Sequencing of and escalation paradigms for MS therapies: time for a rethink?. J Neurol Neurosurg Psychiatry. 2021 Sep;92(9):913. doi: 10.1136/jnnp-2020-325811. Epub 2021 Jun 08. PMID: 34103341.
Copy Download .nbib Format: NLM
Exploring new frontiers in multiple sclerosis.

Nature reviews. Drug discovery

Kingwell K.
PMID: 34611330
Nat Rev Drug Discov. 2021 Nov;20(11):815. doi: 10.1038/d41573-021-00170-z.

No abstract available.

Cite
Kingwell K. Exploring new frontiers in multiple sclerosis. Nat Rev Drug Discov. 2021;20(11):815doi: 10.1038/d41573-021-00170-z.
Kingwell, K. (2021). Exploring new frontiers in multiple sclerosis. Nature reviews. Drug discovery, 20(11), 815. https://doi.org/10.1038/d41573-021-00170-z
Kingwell, Katie. "Exploring new frontiers in multiple sclerosis." Nature reviews. Drug discovery vol. 20,11 (2021): 815. doi: https://doi.org/10.1038/d41573-021-00170-z
Kingwell K. Exploring new frontiers in multiple sclerosis. Nat Rev Drug Discov. 2021 Nov;20(11):815. doi: 10.1038/d41573-021-00170-z. PMID: 34611330.
Copy Download .nbib Format: NLM
Ethical considerations in the treatment of multiple sclerosis fatigue.

Multiple sclerosis and related disorders

Nourbakhsh B, Waubant E, Evers AWM, Solomon AJ.
PMID: 34247106
Mult Scler Relat Disord. 2021 Sep;54:103129. doi: 10.1016/j.msard.2021.103129. Epub 2021 Jul 03.

Fatigue is the most common symptom and a leading cause of disability multiple sclerosis (MS). Despite the lack of evidence, several medications are frequently prescribed by physicians to ameliorate fatigue in patients with MS. However, a recent study demonstrated...

Cite
Nourbakhsh B, Waubant E, Evers AWM, et al. Ethical considerations in the treatment of multiple sclerosis fatigue. Mult Scler Relat Disord. 2021;54:103129doi: 10.1016/j.msard.2021.103129.
Nourbakhsh, B., Waubant, E., Evers, A. W. M., & Solomon, A. J. (2021). Ethical considerations in the treatment of multiple sclerosis fatigue. Multiple sclerosis and related disorders, 54103129. https://doi.org/10.1016/j.msard.2021.103129
Nourbakhsh, Bardia, et al. "Ethical considerations in the treatment of multiple sclerosis fatigue." Multiple sclerosis and related disorders vol. 54 (2021): 103129. doi: https://doi.org/10.1016/j.msard.2021.103129
Nourbakhsh B, Waubant E, Evers AWM, Solomon AJ. Ethical considerations in the treatment of multiple sclerosis fatigue. Mult Scler Relat Disord. 2021 Sep;54:103129. doi: 10.1016/j.msard.2021.103129. Epub 2021 Jul 03. PMID: 34247106.
Copy Download .nbib Format: NLM
OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis.

BMJ open

Dobson R, Craner M, Waddingham E, Miller A, Cavey A, Webb S, Hemingway C, Hobart J, Evangelou N, Scolding N, Rog D, Nicholas R, Marta M, Blain C, Young CA, Ford HL, Matthews PM.
PMID: 34824113
BMJ Open. 2021 Nov 25;11(11):e050176. doi: 10.1136/bmjopen-2021-050176.

INTRODUCTION: The power of 'real world' data to improve our understanding of the clinical aspects of multiple sclerosis (MS) is starting to be realised. Disease modifying therapy (DMT) use across the UK is driven by national prescribing guidelines. As...

Cite
Dobson R, Craner M, Waddingham E, et al. OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis. BMJ Open. 2021;11(11):e050176doi: 10.1136/bmjopen-2021-050176.
Dobson, R., Craner, M., Waddingham, E., Miller, A., Cavey, A., Webb, S., Hemingway, C., Hobart, J., Evangelou, N., Scolding, N., Rog, D., Nicholas, R., Marta, M., Blain, C., Young, C. A., Ford, H. L., & Matthews, P. M. (2021). OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis. BMJ open, 11(11), e050176. https://doi.org/10.1136/bmjopen-2021-050176
Dobson, Ruth, et al. "OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis." BMJ open vol. 11,11 (2021): e050176. doi: https://doi.org/10.1136/bmjopen-2021-050176
Dobson R, Craner M, Waddingham E, Miller A, Cavey A, Webb S, Hemingway C, Hobart J, Evangelou N, Scolding N, Rog D, Nicholas R, Marta M, Blain C, Young CA, Ford HL, Matthews PM. OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis. BMJ Open. 2021 Nov 25;11(11):e050176. doi: 10.1136/bmjopen-2021-050176. PMID: 34824113; PMCID: PMC8627413.
Copy Download .nbib Format: NLM
COVID-19 vaccines and multiple sclerosis disease-modifying therapies.

Multiple sclerosis and related disorders

Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA, Baker D.
PMID: 34358943
Mult Scler Relat Disord. 2021 Aug;53:103155. doi: 10.1016/j.msard.2021.103155. Epub 2021 Jul 18.

No abstract available.

Cite
Giovannoni G, Hawkes CH, Lechner-Scott J, et al. COVID-19 vaccines and multiple sclerosis disease-modifying therapies. Mult Scler Relat Disord. 2021;53:103155doi: 10.1016/j.msard.2021.103155.
Giovannoni, G., Hawkes, C. H., Lechner-Scott, J., Levy, M., Yeh, E. A., & Baker, D. (2021). COVID-19 vaccines and multiple sclerosis disease-modifying therapies. Multiple sclerosis and related disorders, 53103155. https://doi.org/10.1016/j.msard.2021.103155
Giovannoni, Gavin, et al. "COVID-19 vaccines and multiple sclerosis disease-modifying therapies." Multiple sclerosis and related disorders vol. 53 (2021): 103155. doi: https://doi.org/10.1016/j.msard.2021.103155
Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA, Baker D. COVID-19 vaccines and multiple sclerosis disease-modifying therapies. Mult Scler Relat Disord. 2021 Aug;53:103155. doi: 10.1016/j.msard.2021.103155. Epub 2021 Jul 18. PMID: 34358943; PMCID: PMC8286545.
Copy Download .nbib Format: NLM
Disease-modifying therapy usage in patients with multiple sclerosis in France: A 6-year population-based study.

Revue neurologique

Leblanc S, Roux J, Tillaut H, Le Page E, Leray E.
PMID: 34253346
Rev Neurol (Paris). 2021 Dec;177(10):1250-1261. doi: 10.1016/j.neurol.2021.04.006. Epub 2021 Jul 10.

BACKGROUND: Most data regarding the use of disease-modifying therapies (DMTs) in multiple sclerosis (MS) comes from clinical series or regional databases that have a risk of recruitment bias. French health administrative data offers the significant advantage of being extensive...

Cite
Leblanc S, Roux J, Tillaut H, et al. Disease-modifying therapy usage in patients with multiple sclerosis in France: A 6-year population-based study. Rev Neurol (Paris). 2021;177(10):1250-1261doi: 10.1016/j.neurol.2021.04.006.
Leblanc, S., Roux, J., Tillaut, H., Le Page, E., & Leray, E. (2021). Disease-modifying therapy usage in patients with multiple sclerosis in France: A 6-year population-based study. Revue neurologique, 177(10), 1250-1261. https://doi.org/10.1016/j.neurol.2021.04.006
Leblanc, S, et al. "Disease-modifying therapy usage in patients with multiple sclerosis in France: A 6-year population-based study." Revue neurologique vol. 177,10 (2021): 1250-1261. doi: https://doi.org/10.1016/j.neurol.2021.04.006
Leblanc S, Roux J, Tillaut H, Le Page E, Leray E. Disease-modifying therapy usage in patients with multiple sclerosis in France: A 6-year population-based study. Rev Neurol (Paris). 2021 Dec;177(10):1250-1261. doi: 10.1016/j.neurol.2021.04.006. Epub 2021 Jul 10. PMID: 34253346.
Copy Download .nbib Format: NLM
Showing 37 to 46 of 46 entries